Travere CEO sells 400K shares after option exercise

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) reported that Chief Executive Officer and director Eric M. Dube exercised employee stock options for a total of 400,000 shares of common stock at an exercise price of $23.34 per share on September 15–17, 2026, and sold 400,000 shares of common stock in open-market transactions on the same dates. The sales were made under a written trading plan adopted on June 16, 2026, that meets Rule 10b5-1(c) requirements, and the options exercised were fully vested and exercisable.

Insider Trade Summary 10b5-1

Exercise and Sale: 400,000 shares ($16.05M approx. pre-tax spread)

Exercise and Sale 14 txns

Insider Dube Eric M

Role CHIEF EXECUTIVE OFFICER

Sold 400,000 shs ($25.39M)

Approx. gross sale proceeds $25.39M

Approx. exercise cost $9.34M

Approx. pre-tax spread $16.05M

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy) F9	108,493	$0.00	$0.00
Exercise	Common Stock	108,493	$23.34	$2.53M
Sale	Common Stock F1, F7	101,691	$64.5866	$6.57M
Sale	Common Stock F1, F8	6,802	$64.9508	$442K
Exercise	Employee stock option (right to buy) F9	195,841	$0.00	$0.00
Exercise	Common Stock	195,841	$23.34	$4.57M
Sale	Common Stock F1, F5	99,716	$63.2593	$6.31M
Sale	Common Stock F1, F6	96,125	$63.6389	$6.12M
Exercise	Employee stock option (right to buy) F9	95,666	$0.00	$0.00
Exercise	Common Stock	95,666	$23.34	$2.23M
Sale	Common Stock F1, F2	63,498	$61.9945	$3.94M
Sale	Common Stock F1, F3	28,796	$62.6553	$1.80M
Sale	Common Stock F1, F4	3,102	$63.6434	$197K
Sale	Common Stock F1	270	$65.31	$18K

Holdings After Transaction: Employee stock option (right to buy) — 0 contracts (Direct); Common Stock — 432,886 shares (Direct)

Footnotes (9)

1. F1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
2. F2. The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
3. F3. The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
4. F4. The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
5. F5. The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
6. F6. The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
7. F7. The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
8. F8. The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
9. F9. The stock option is fully vested and exercisable.

Key Figures

Options exercised: 400,000 shares Shares sold: 400,000 shares Option exercise price: $23.34 per share +4 more

7 metrics

Options exercised 400,000 shares Total employee stock options exercised into common stock on September 15–17, 2026

Shares sold 400,000 shares Total Travere Therapeutics common shares sold on September 15–17, 2026

Option exercise price $23.34 per share Exercise price for employee stock options converted into common stock

Weighted average sale price $61.9945 per share One of the reported weighted average sale prices with a range of $61.405–$62.40

Highest weighted average sale price $64.9508 per share Reported weighted average price for one transaction, range $64.84–$65.14

Option expiration date January 4, 2029 Expiration date of the employee stock options that were exercised

Rule 10b5-1 plan adoption date June 16, 2026 Date the written trading plan governing the sales was adopted

Key Terms

Rule 10b5-1(c), Employee stock option (right to buy), weighted average sale price, Common Stock

4 terms

Rule 10b5-1(c) regulatory

"written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

Employee stock option (right to buy) financial

"security titled Employee stock option (right to buy) was exercised into common stock"

weighted average sale price financial

"The weighted average sale price for the transaction reported was $61.9945"

Common Stock financial

"underlying security title for the options exercised was Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TVTX report for its CEO in this Form 4?

The CEO, Eric M. Dube, exercised 400,000 stock options at $23.34 per share and sold 400,000 shares of Travere Therapeutics common stock in open-market transactions on September 15–17, 2026.

Over what dates did the TVTX CEO’s option exercises and share sales occur?

Eric M. Dube’s reported transactions occurred on September 15, 16, and 17, 2026, with option exercises and corresponding sales of Travere Therapeutics common stock on each of those dates.

Were the TVTX CEO’s September 2026 share sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales were made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

What was the exercise price of the Travere Therapeutics (TVTX) stock options exercised?

The employee stock options exercised by the CEO in September 2026 had an exercise price of $23.34 per share, with each exercise converting options into an equal number of Travere Therapeutics common shares.

What price ranges were involved in the TVTX CEO’s share sales?

Weighted average sale prices ranged from $61.9945 to $64.9508 per share, with individual sale price ranges on different trades spanning from $61.405 up to $65.14, as detailed in the transaction footnotes.

Were the Travere Therapeutics stock options exercised by the CEO vested?

Yes. A footnote states that the stock option is fully vested and exercisable, indicating the CEO exercised already-vested employee stock options into common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 09:32 PM Accepted by SEC EDGAR 09/17/2026 - 09:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Eric M

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M		95,666	A	$23.34	528,552	D
Common Stock	09/15/2026		S(1)		63,498	D	$61.9945(2)	465,054	D
Common Stock	09/15/2026		S(1)		28,796	D	$62.6553(3)	436,258	D
Common Stock	09/15/2026		S(1)		3,102	D	$63.6434(4)	433,156	D
Common Stock	09/15/2026		S(1)		270	D	$65.31	432,886	D
Common Stock	09/16/2026		M		195,841	A	$23.34	628,727	D
Common Stock	09/16/2026		S(1)		99,716	D	$63.2593(5)	529,011	D
Common Stock	09/16/2026		S(1)		96,125	D	$63.6389(6)	432,886	D
Common Stock	09/17/2026		M		108,493	A	$23.34	541,379	D
Common Stock	09/17/2026		S(1)		101,691	D	$64.5866(7)	439,688	D
Common Stock	09/17/2026		S(1)		6,802	D	$64.9508(8)	432,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$23.34	09/15/2026		M			95,666	(9)	01/04/2029	Common Stock	95,666	$0	304,334	D
Employee stock option (right to buy)	$23.34	09/16/2026		M			195,841	(9)	01/04/2029	Common Stock	195,841	$0	108,493	D
Employee stock option (right to buy)	$23.34	09/17/2026		M			108,493	(9)	01/04/2029	Common Stock	108,493	$0	0	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

5. The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

6. The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

7. The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

8. The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

9. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)